Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Orexigen Therapeutics Inc. OREXQ

"Orexigen is an emerging pharmaceutical company, focusing on developing neuroscience drugs. The company screens older drugs seeking synergistic actions. The company's most advanced drug candidates target obesity."


OTCPK:OREXQ - Post by User

Bullboard Posts
Post by insiderinfocanon Dec 07, 2010 5:05pm
428 Views
Post# 17814680

First Prescription Diet Pill in a Decade

First Prescription Diet Pill in a Decade

Can't wait for the halt to be over.

Orexigen Wins Panel's Backing for First Prescription Diet Pill in a Decade

By Catherine Larkin - Dec 7, 2010 1:21 PM PT

Orexigen Therapeutics Inc. won a U.S. panel’s backing for Contrave, a new prescription diet pill.

Contrave’s benefits in helping obese people lose weight are greater than the drug’s potential long-term risks, outside advisers to the Food and Drug Administration said today in a 13- 7 vote at the agency’s headquarters in Silver Spring, Maryland. The panel earlier said a study of Contrave’s heart risks should be done after approval. The FDA usually follows its advisers’ recommendations and is scheduled to make a decision on approval by Jan. 31.

Bullboard Posts